Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
40,364,253
-
Share change
-
+458,482
-
Total reported value
-
$414,121,139
-
Put/Call ratio
-
13%
-
Price per share
-
$10.26
-
Number of holders
-
80
-
Value change
-
-$490,145
-
Number of buys
-
45
-
Number of sells
-
36
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q4 2022
As of 31 Dec 2022,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,364,253 shares.
The largest 10 holders included
SR ONE CAPITAL MANAGEMENT, LP, Cormorant Asset Management, LP, BlackRock Inc., STATE STREET CORP, RA CAPITAL MANAGEMENT, L.P., Logos Global Management LP, CITADEL ADVISORS LLC, Avoro Capital Advisors LLC, VANGUARD GROUP INC, and FMR LLC.
This page lists
79
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.